Identification of chronic myeloid leukemia patients treated with imatinib who are potentially eligible for treatment discontinuation by assessing real-life molecular responses on the international scale in a EUTOS-certified lab

•Real-life molecular responses on international scale in EUTOS-certified laboratory.•53.4% of patients were in deep molecular responses ≥MR4.5 at last visit.•36.2% of patients had ≥MR4.5 and were treated for >5.8 years; 26.7% for >8 years.•Potential patients for treatment-free remission attempt outside clinical trials were identified.